Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Over recent decades, an improved understanding of the pathophysiology of type 2 diabetes mellitus (T2DM) and glucose regulation has led to innovative research and new treatment paradigms. The discovery of the gut peptide glucagon-like peptide-1 (GLP-1) and its role in glucose regulation paved the way for the class of GLP-1 receptor agonist compounds, or GLP-1RAs. The long-acting GLP-1RAs (dulaglutide, exenatide extended-release, liraglutide, semaglutide [injectable and oral]) are classified as such based on a minimum 24-hour duration of clinically relevant effects after administration. In phase 3 clinical trial programs of long-acting GLP-1RAs, A1C typically was reduced in the range of 1% to 1.5%, with reductions close to 2% in some studies. GLP-1RAs when used alone (without sulfonylureas or insulin) have a low risk of hypoglycemia because, like endogenous GLP-1, their insulinotropic effects are glucose-dependent. In addition to local actions in the gastrointestinal (GI) tract, GLP-1RAs stimulate receptors in the central nervous system to increase satiety, resulting in weight loss. All long-acting GLP-1RAs have, at minimum, been shown to be safe and not increase cardiovascular (CV) risk and most (liraglutide, semaglutide injectable, dulaglutide, albiglutide) have been shown in CV outcomes trials (CVOTs) to significantly reduce the risk of major cardiac adverse events. The class has good tolerability overall, with generally transient GI adverse events being most common. The weekly injectable agents offer scheduling convenience and may promote treatment adherence. One long-acting GLP-1RA is available as an oral daily tablet, which may be preferable for some patients and providers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Research works printed but not linked: 45
- Cannon, 2018, Burden of illness in type 2 diabetes mellitus, J Manag Care Spec Pharm, 24, S5
- Bradshaw Kaiser, 2018, Global prevalence of type 2 diabetes over the next ten years (2018-2028), Diabetes, 67
- Ahrén, 2019, Glucagon-like peptide-1 receptor agonists for type 2 diabetes: a rational drug development, J Diabetes Investig, 10, 196, 10.1111/jdi.12911 · DOI
- Holst, 2019, From the incretin concept and the discovery of GLP-1 to today's diabetes therapy, Front Endocrinol (Lausanne), 10, 260, 10.3389/fendo.2019.00260 · DOI · Paper page
- DeFronzo, 2013, Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes, Diabetes Care, 36, S127, 10.2337/dcS13-2011 · DOI · Paper page
- Hui, 2002, The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects, Eur J Endocrinol, 146, 863, 10.1530/eje.0.1460863 · DOI
- Sharma, 2018, Recent updates on GLP-1 agonists: current advancements & challenges, Biomed Pharmacother, 108, 952, 10.1016/j.biopha.2018.08.088 · DOI · Paper page
- Holst, 2019, Long-acting glucagon-like peptide-1 receptor agonist—Status December 2018, Ann Transl Med, 7, 83, 10.21037/atm.2019.01.09 · DOI
- Tella, 2015, Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance, Ther Adv Endocrinol Metab, 6, 109, 10.1177/2042018815580257 · DOI
- Marre, 2009, Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU), Diabet Med, 26, 268, 10.1111/j.1464-5491.2009.02666.x · DOI · Paper page
- Garber, 2011, Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes, Diabetes Obes Metab, 13, 348, 10.1111/j.1463-1326.2010.01356.x · DOI · Paper page
- Bergenstal, 2010, Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial, Lancet, 376, 431, 10.1016/S0140-6736(10)60590-9 · DOI · Paper page
- Russell-Jones, 2012, Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study, Diabetes Care, 35, 252, 10.2337/dc11-1107 · DOI · Paper page
- Buse, 2013, Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study, Lancet, 381, 117, 10.1016/S0140-6736(12)61267-7 · DOI · Paper page
- Guja, 2018, Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: the DURATION-7 randomized study, Diabetes Obes Metab, 20, 1602, 10.1111/dom.13266 · DOI
- Frías, 2016, Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial, Lancet Diabetes Endocrinol, 4, 1004, 10.1016/S2213-8587(16)30267-4 · DOI · Paper page
- Wysham, 2015, Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial, Mayo Clin Proc, 90, 356, 10.1016/j.mayocp.2015.01.008 · DOI
- Umpierrez, 2014, Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3), Diabetes Care, 37, 2168, 10.2337/dc13-2759 · DOI · Paper page
- Blonde, 2015, Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study, Lancet, 385, 2057, 10.1016/S0140-6736(15)60936-9 · DOI · Paper page
- Dungan, 2016, A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8), Diabetes Obes Metab, 18, 475, 10.1111/dom.12634 · DOI · Paper page
- Aroda, 2017, Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial, Lancet Diabetes Endocrinol, 5, 355, 10.1016/S2213-8587(17)30085-2 · DOI · Paper page
- Pratley, 2018, Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial, Lancet Diabetes Endocrinol, 6, 275, 10.1016/S2213-8587(18)30024-X · DOI · Paper page
- Rosenstock, 2019, Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial, JAMA, 321, 1466, 10.1001/jama.2019.2942 · DOI · Paper page
- Pereira, 2019, Emerging role of SGLT-2 inhibitors for the treatment of obesity, Drugs, 79, 219, 10.1007/s40265-019-1057-0 · DOI · Paper page
- Brown, 2019, Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: mechanistic possibilities, Obes Rev, 20, 816, 10.1111/obr.12841 · DOI · Paper page
- Gerstein, 2008, Effects of intensive glucose lowering in type 2 diabetes, N Engl J Med, 358, 2545, 10.1056/NEJMoa0802743 · DOI · Paper page
- Patel, 2008, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, N Engl J Med, 358, 2560, 10.1056/NEJMoa0802987 · DOI · Paper page
- Duckworth, 2009, Glucose control and vascular complications in veterans with type 2 diabetes, N Engl J Med, 360, 129, 10.1056/NEJMoa0808431 · DOI · Paper page
- Holman, 2017, Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes, N Engl J Med, 377, 1228, 10.1056/NEJMoa1612917 · DOI · Paper page
- Gerstein, 2019, Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial, Lancet, 394, 121, 10.1016/S0140-6736(19)31149-3 · DOI · Paper page
- Husain, 2019, Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med, 381, 841, 10.1056/NEJMoa1901118 · DOI · Paper page
- Raccah, 2017, Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues, Expert Opin Drug Saf, 16, 227
- Madsbad, 2016, Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists, Diabetes Obes Metab, 18, 317, 10.1111/dom.12596 · DOI · Paper page
- Bethel, 2018, Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis, Lancet Diabetes Endocrinol, 6, 105, 10.1016/S2213-8587(17)30412-6 · DOI · Paper page
- Dicembrini, 2017, Erratum to: Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials, Acta Diabetol, 54, 1069, 10.1007/s00592-017-1049-z · DOI
- Avgerinos, 2019, Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: a systematic review and meta-analysis, Diabetes Obes Metab, 21, 188, 10.1111/dom.13484 · DOI
- Wang, 2018, Incretin-based therapies and diabetic retinopathy: real-world evidence in older U.S. adults, Diabetes Care, 41, 1998, 10.2337/dc17-2285 · DOI
- Feldman-Billard, 2018, Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes, Diabetes Metab, 44, 4, 10.1016/j.diabet.2017.10.014 · DOI · Paper page
- Bain, 2019, Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review, Diabetes Obes Metab, 21, 454, 10.1111/dom.13538 · DOI · Paper page
- Solomon, 2017, Diabetic retinopathy: a position statement by the American Diabetes Association, Diabetes Care, 40, 412, 10.2337/dc16-2641 · DOI · Paper page
- Iglay, 2015, Systematic literature review and meta-analysis of medication adherence with once-weekly versus once-daily therapy, Clin Ther, 37, 1813, 10.1016/j.clinthera.2015.05.505 · DOI
- Kishimoto, 2015, Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA, Arch Osteoporos, 10, 231, 10.1007/s11657-015-0231-6 · DOI
- Qin, 2017, Glucagon-like peptide-1 receptor agonist treatment attributes important to injection-naïve patients with type 2 diabetes mellitus: a multinational preference study, Diabetes Ther, 8, 321, 10.1007/s13300-017-0230-2 · DOI
- Johnston, 2014, Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States, Adv Ther, 31, 1119, 10.1007/s12325-014-0166-0 · DOI
- Nguyen, 2017, Glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy adherence for patients with type 2 diabetes in a Medicare population, Adv Ther, 34, 658, 10.1007/s12325-016-0470-y · DOI · Paper page
Cited by
Tuttle, K. R., Bosch-Traberg, H., Cherney, D. Z. I., Hadjadj, S., Lawson, J., Mosenzon, O., Rasmussen, S., & Bain, S. C. (2023) · Kidney International · doi:10.1016/j.kint.2022.12.028 · Cited by 124
The incretin/glucagon system as a target for pharmacotherapy of obesity
Del Prato, S., Gallwitz, B., Holst, J. J., & Meier, J. J. (2022) · Obesity Reviews · doi:10.1111/obr.13372 · Cited by 77
“(CNS), including dulaglutide, exenatide extended-release, and semaglutide, have since been developed and reduce bodyweight to a similar ( 2%–3%) or, in the case of injectable semaglutide, greater ( 4%–6%) extent as liraglutide with a similar tolerability profile in humans.(68)”
BackgroundGhazanfar, H., Javed, N., Qasim, A., Sosa, F., Altaf, F., Khan, S., Mahasamudram, J., Jyala, A., Kandhi, S. D., Shin, D., et al. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i26.3221 · Cited by 23
“GLP-1 RA includes human analogues (Albiglutide, Dulaglutide, Liraglutide, Semaglutide) and exendin-4 derivatives (Exenatide, Lixisenatide) are effective in reducing postprandial hyperglycemia[2].”
Caballero Mateos, I., García de Lucas, M. D., Doulatram-Gamgaram, V. K., Moreno-Moreno, P., Jimenez-Millan, A. I., Botana-López, M., Merino-Torres, J. F., Soto-Gónzalez, A., Fernández-García, J. C., & Morales-Portillo, C. (2024) · Nutrients · doi:10.3390/nu16152545 · Cited by 8
“Compared to other glucose-lowering drugs, GLP-1 RAs are highly effective at improving glycemic control and reducing body weight and blood pressure while showing a cardioprotective effect and involving a low risk of hypoglycemia [8,13,14].”
Background
Metadata
- Authors
- Chun, J. H., & Butts, A.
- Venue
- JAAPA
- Published
- 2020-08
- Volume
- 33
- Issue
- S8
- Pages
- 3-18
- ISSN
- 0893-7400 (ISSN-L)
- 1547-1896
- OpenAlex
- W3045885164
- Cited by
- 45
- References
- 47
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management. https://app.cochat.ai/papers/10.1097/01.jaa.0000669456.13763.bd
- The paper
- Chun, J. H., & Butts, A. (2020). Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management. JAAPA. https://doi.org/10.1097/01.jaa.0000669456.13763.bd
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.